SCHEMBL6487331

SCHEMBL6487331

CCc1ccc(-c2ccc(F)cc2)c(C(=O)Nc2ccc(NCCc3ccccn3)cc2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.49
KMT2A Q03164 5/20 0.49
MAPT P10636 4/20 0.49
GAA P10253 2/20 0.49
KDM4E B2RXH2 2/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
CTNNB1 P35222 2/20 0.49
TCF7L2 Q9NQB0 2/20 0.49
HTT P42858 2/20 0.47
RAB9A P51151 3/20 0.44
LMNA P02545 3/20 0.44
NPC1 O15118 2/20 0.44
PDPK1 O15530 1/20 0.44
NAMPT P43490 2/20 0.44
GRM2 Q14416 1/20 0.42
ALDH1A1 P00352 2/20 0.42
MAOB P27338 1/20 0.42
POLB P06746 1/20 0.42
TSHR P16473 1/20 0.42
HPGD P15428 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6498179 0.93 RAB9A (0.47) MEN1KMT2AMAPTGAAKDM4E
SCHEMBL6500397 0.93 CTNNB1 (0.47) MEN1KMT2AMAPTGAAKDM4E
SCHEMBL6500930 0.92 CNR1 (0.51) MEN1KMT2AMAPTGAAKDM4E
SCHEMBL6487583 0.90 HTT (0.52) MEN1KMT2AMAPTGAAKDM4E
SCHEMBL6501416 0.90 SMO (0.51) MEN1KMT2AMAPTL3MBTL1HTT
SCHEMBL6490637 0.89 CTNNB1 (0.54) MEN1KMT2AMAPTGAAKDM4E
SCHEMBL6489333 0.88 TAS1R3 (0.53) MEN1KMT2AMAPTGAAKDM4E
SCHEMBL6490335 0.88 CNR1 (0.52) MEN1KMT2AMAPTGAAKDM4E
SCHEMBL6788552 0.88 RAB9A (0.51) MEN1KMT2AMAPTGAAKDM4E
SCHEMBL6489399 0.87 NPC1 (0.47) MEN1KMT2AMAPTGAAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 MEN1 1991/4885KMT2A 573/4885MAPT 4202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.